Home › Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal Antibody at Icaac
 

Keywords :   


Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal Antibody at Icaac

2014-09-07 08:03:23| Biotech - Topix.net

Novavax, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today presented preclinical data demonstrating that antibodies generated to its RSV F-protein nanoparticle vaccine candidate bind to the site II epitope of the RSV F-protein with a higher affinity than palivizumab at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, DC. In poster session 024: I-314b titled "Development and Characterization of Recombinant RSV Nanoparticle Vaccine Induced Monoclonal Antibody."

Tags: data presents induced antibody

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Hurricane Isaac Graphics
29.09Hurricane Isaac Forecast Discussion Number 13
29.09Tropical Storm Joyce Graphics
29.09Hurricane Isaac Wind Speed Probabilities Number 13
29.09Hurricane Isaac Public Advisory Number 13
29.09Summary for Hurricane Isaac (AT5/AL102024)
29.09Tropical Storm Joyce Wind Speed Probabilities Number 7
29.09Tropical Storm Joyce Forecast Discussion Number 7
More »